4.7 Article

3D QSAR pharmacophore based lead identification of G9a lysine methyltransferase towards epigenetic therapeutics

期刊

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
卷 41, 期 18, 页码 8635-8653

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/07391102.2022.2135600

关键词

ADMET; Cancer; Chromatin; Histone PTM; MD Simulation; Molecular docking; QSAR

向作者/读者索取更多资源

This study conducted computational investigations to find novel and safer inhibitors against G9a, an excellent epigenetic target. Through screening and comparative analysis, a lead inhibitor with better binding efficacy and a safer ADMET profile was identified. The results were further validated using molecular dynamics simulation and binding energy calculation. This study represents the first attempt of in silico screening of a large natural compound library against G9a.
The G9a, Lysine Methyltransferase that methylates the histone 3 lysine 9 (H3K9) of the nucleosome, is an excellent epigenetic target having no clinically passed inhibitor currently owing to adverse in vivo ADMET toxicities. In this work, we have carried out detailed computational investigations to find novel and safer lead against the target using advanced 3 D QSAR pharmacophore screening of databases containing more than 400000 entrees of natural compounds. The screening was conducted at different levels at increasing stringencies by employing pharmacophore mapping, druglikenesses and interaction profiles of the selected to identify potential hit compounds. The potential hits were further screened by advanced flexible docking, ADME and toxicity analysis to eight hit compounds. Based on the comparative analysis of the hits with the reference inhibitor, we identified one lead inhibitor against the G9a, having better binding efficacy and a safer ADMET profile than the reference inhibitor. Finally, the results were further verified using robust molecular dynamics simulation and MM-GBSA binding energy calculation. The natural compounds are generally considered benign due to their long human uses and this is the first attempt of in silico screening of a large natural compound library against G9a to our best knowledge. Therefore, the finding of this study may add value towards the development of epigenetic therapeutics against the G9a. Communicated by Ramaswamy H. Sarma

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据